Anti-oxidant and Metabolic Phenotype in Regulating Tumor Specific T cell Memory Response
抗氧化和代谢表型调节肿瘤特异性 T 细胞记忆反应
基本信息
- 批准号:9917102
- 负责人:
- 金额:$ 52.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-12-01 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:AcidsAdoptive Cell TransfersAdoptive TransferAntioxidantsBiological MarkersCell surfaceCellsCitric Acid CycleClinicClinicalComplementDataDevelopmentEffectivenessEnsureEpigenetic ProcessEpitopesEventExhibitsFRAP1 geneGenerationsGlycolysisHumanHuman EngineeringImmunosuppressionImmunotherapyKnockout MiceKnowledgeLeadLongevityMalignant NeoplasmsMeasuresMediatingMembrane PotentialsMemoryMetabolicMetabolic PathwayMetabolismMouse StrainsMusOutcomeOxidation-ReductionOxidative PhosphorylationOxidative StressPathway interactionsPatientsPentosephosphate PathwayPhenotypePlayPopulationPost-Translational Protein ProcessingPropertyProtocols documentationRecombinantsRecurrenceReportingRetroviral VectorRoleSignaling MoleculeSulfhydryl CompoundsSurfaceT cell differentiationT cell responseT cell therapyT memory cellT-Cell DevelopmentT-LymphocyteTXN geneTranscription Factor AP-1Transgenic MiceTranslationsTreatment EfficacyTumor Immunityalpha ketoglutarateexperimental studyglucose uptakeimprovedin vitro activityin vivoinnovationmetabolic phenotypemitochondrial membranemitochondrial metabolismoverexpressionpluripotencyprogramsresponsestem cellsstem-like cellsubcutaneoustumortumor growthtumor microenvironment
项目摘要
ABSTRACT
New strategies to improve adoptive cell therapy (ACT) protocols are now emerging to enhance in vivo
persistence of adoptively transferred tumor epitope specific T cells and overcome tumor-induced
immunosuppression. Our preliminary data suggests that there is a direct correlation between the long-lived
central memory T cells (Tcm) and its anti-oxidant capacity. Overexpression of thioredoxin-1 (Trx), a key
molecule that regulates cell-surface thiols (c-SH), resulted in increased Tcm phenotype in T cells obtained from
TCR transgenic mouse crossbred with Trx transgenic mouse, or engineering human T cells with retroviral
vector with TCR and Trx together. Further, a quantification of the metabolites within Pmel vs. Pmel-Trx cells
showed that metabolites from pentose-phosphate pathway (PPP) and tricarboxylic acid cycle (TCA)
intermediate alpha-ketoglutarate (α-KG) were significantly higher in Pmel-Trx T cells as compared to Pmel
cells. While reductive intermediates generated by PPP are important to overcome oxidative stress, recent
reports have shown that α-KG is important in extending the cellular lifespan and regulating pluripotency of
stem cells. These preliminary observations lead us to hypothesize that “the presence of Trx drives tumor
reactive T cells to a c-SHhi phenotype, which not only exhibits enhanced anti-oxidant phenotype, but regulates
a combination of events including post-translational modifications, and epigenetic stability that lead to
metabolically fit anti-tumor T cells”. We propose the following specific aims: 1) To determine how the level of
thiol/thioredoxin on the surface of T cells regulates the generation of tumor reactive Tcm/Tscm cells in vivo, 2)
To determine how changes in the metabolic pathways and metabolites in T cells regulate the generation of
tumor reactive Tcm/Tscm in vivo, 3) To determine if modulation of reduced thiols and/or metabolites results in
generation of tumor reactive TCR transduced human T cells with functional memory phenotype. We believe
that our studies are innovative and will uncover important aspects that need to be considered when generating
tumor specific Tcm/Tscm cells for ACT.
抽象的
改进过继细胞疗法 (ACT) 方案的新策略现已出现,以增强体内
过继转移的肿瘤表位特异性 T 细胞的持久性并克服肿瘤诱导的
我们的初步数据表明,长寿之间存在直接相关性。
中枢记忆 T 细胞 (Tcm) 及其抗氧化能力,硫氧还蛋白-1 (Trx) 的过度表达是关键。
调节细胞表面硫醇 (c-SH) 的分子,导致从 T 细胞中获得的 Tcm 表型增加
TCR 转基因小鼠与 Trx 转基因小鼠杂交,或用逆转录病毒改造人类 T 细胞
载体与 TCR 和 Trx 一起此外,对 Pmel 与 Pmel-Trx 细胞内的代谢物进行定量。
显示来自戊糖磷酸途径(PPP)和三羧酸循环(TCA)的代谢物
与 Pmel 相比,Pmel-Trx T 细胞中的中间体 α-酮戊二酸 (α-KG) 显着更高
虽然 PPP 产生的还原中间体对于克服氧化应激很重要,但最近
报告表明,α-KG 对于延长细胞寿命和调节细胞的多能性非常重要
这些初步观察使我们认识到“Trx 的存在驱动肿瘤”。
反应性 T 细胞形成 c-SHhi 表型,不仅表现出增强的抗氧化表型,而且调节
包括翻译后修饰和表观遗传稳定性在内的事件组合
“代谢适合的抗肿瘤 T 细胞”提出以下具体目标:1)确定 T 细胞的水平如何。
T细胞表面的硫醇/硫氧还蛋白调节体内反应性肿瘤Tcm/Tscm细胞的生成,2)
确定 T 细胞代谢途径和代谢物的变化如何调节 T 细胞的产生
体内反应性肿瘤 Tcm/Tscm,3) 确定还原硫醇和/或代谢物的调节是否会导致
我们相信,具有功能性记忆表型的肿瘤反应性 TCR 转导人类 T 细胞的产生。
我们的研究具有创新性,将揭示生成时需要考虑的重要方面
用于 ACT 的肿瘤特异性 Tcm/Tscm 细胞。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shikhar Mehrotra其他文献
Shikhar Mehrotra的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shikhar Mehrotra', 18)}}的其他基金
Increasing Thiols for Improving T cell Immunotherapy
增加硫醇以改善 T 细胞免疫治疗
- 批准号:
10603006 - 财政年份:2022
- 资助金额:
$ 52.24万 - 项目类别:
Intersections of RNA-binding proteins and T-cells in oral epithelial plasticity
RNA结合蛋白和T细胞在口腔上皮可塑性中的交叉点
- 批准号:
10417171 - 财政年份:2020
- 资助金额:
$ 52.24万 - 项目类别:
Understanding Metabolic and Epigenetic Cross‐ talk in Potent Anti‐ tumor T cells
了解强效抗肿瘤 T 细胞中的代谢和表观遗传交叉对话
- 批准号:
10400117 - 财政年份:2020
- 资助金额:
$ 52.24万 - 项目类别:
Intersections of RNA-binding proteins and T-cells in oral epithelial plasticity
RNA结合蛋白和T细胞在口腔上皮可塑性中的交叉点
- 批准号:
10178000 - 财政年份:2020
- 资助金额:
$ 52.24万 - 项目类别:
Programming Metabolically Fit TILs for Immunotherapy
为免疫疗法编程适合代谢的 TIL
- 批准号:
9906726 - 财政年份:2020
- 资助金额:
$ 52.24万 - 项目类别:
Understanding Metabolic and Epigenetic Cross‐ talk in Potent Anti‐ tumor T cells
了解强效抗肿瘤 T 细胞中的代谢和表观遗传交叉对话
- 批准号:
10599308 - 财政年份:2020
- 资助金额:
$ 52.24万 - 项目类别:
Understanding Metabolic and Epigenetic Cross‐ talk in Potent Anti‐ tumor T cells
了解强效抗肿瘤 T 细胞中的代谢和表观遗传交叉对话
- 批准号:
10163144 - 财政年份:2020
- 资助金额:
$ 52.24万 - 项目类别:
Programming Metabolically Fit TILs for Immunotherapy
为免疫疗法编程适合代谢的 TIL
- 批准号:
10822377 - 财政年份:2020
- 资助金额:
$ 52.24万 - 项目类别:
Intersections of RNA-binding proteins and T-cells in oral epithelial plasticity
RNA结合蛋白和T细胞在口腔上皮可塑性中的交叉点
- 批准号:
10632129 - 财政年份:2020
- 资助金额:
$ 52.24万 - 项目类别:
Anti-oxidant and Metabolic Phenotype in Regulating Tumor Specific T cell Memory Response
抗氧化和代谢表型调节肿瘤特异性 T 细胞记忆反应
- 批准号:
10300448 - 财政年份:2019
- 资助金额:
$ 52.24万 - 项目类别:
相似国自然基金
CMV特异性T细胞回输促进受者内源性抗CMV免疫重建的机制研究
- 批准号:81900137
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
STAT/IRF-8通路在髓源性抑制细胞(MDSCs)诱导肝移植免疫耐受过程中的机制研究
- 批准号:81401320
- 批准年份:2014
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
HBV特异性免疫效应细胞预防肝移植术后乙肝复发的研究
- 批准号:81170444
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
肾固有树突状细胞在肾脏缺血再灌注损伤中的作用及其机制
- 批准号:81170690
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
Olig修饰的神经干细胞移植联合MBP活化的T细胞过继免疫治疗脊髓损伤
- 批准号:81071268
- 批准年份:2010
- 资助金额:34.0 万元
- 项目类别:面上项目
相似海外基金
Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
- 批准号:
10751133 - 财政年份:2023
- 资助金额:
$ 52.24万 - 项目类别:
Therapeutic applications of CD4+ T cells specific for oncogenic driver mutations
致癌驱动突变特异性 CD4 T 细胞的治疗应用
- 批准号:
10640078 - 财政年份:2020
- 资助金额:
$ 52.24万 - 项目类别: